Head-to-head · Cost-Efficiency Index
Science & Co vs Navio MD
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
Science & Co
A twelve-month committer, or someone who values a company stating plainly what it is and is not.
Visit Science & CoNavio MD
Shoppers who want compounded tirzepatide with a brand-name fallback path on the same platform, 48 states.
Visit Navio MDThe verdict
Science & Co takes it, leading the Cost-Efficiency Index 74 to 73. Declares in its own footer that it is not a compounding facility, and explains its own asterisk in its own FAQ — two disclosures most of this market never makes. Navio MD still earns a C — Shoppers who want compounded tirzepatide with a brand-name fallback path on the same platform, 48 states.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the ranking). See how it stacks up: CoreAge Rx vs Science & Co.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | Science & Co | Navio MD |
|---|---|---|
| Cost-Efficiency Index | 74/100 | 73/100 |
| Semaglutide / mo | $149/mo month-to-month; $79 only on a twelve-month plan | $345/mo (brand Ozempic) |
| Tirzepatide / mo | $199/mo month-to-month; $125 only on a twelve-month plan | $189/mo (starting dose, compounded) |
| Semaglutide / yr (modeled) | $1,788 | $4,140 |
| Tirzepatide / yr (modeled) | $2,388 | $2,268 |
| Coverage | Not disclosed | 48 states |
| Oral / sublingual | No | No |
| Brand-name access | Compounded only | Yes |
| Rank here | #62 | #69 |
Science & Co
74/100Where the value is
- States twice in its footer that "Science and Co, Inc. is not a 503A or 503B compounding facility"
- Its own FAQ names the commitment behind the headline: "Plans start at $79 a month on the 12 month plan"
- The printed saving corroborates the reference price — 79 divided by 149 is 53%, exactly the "Save 47%" shown
The tradeoffs
- The number it leads with is a twelve-month commitment; the per-month rates are $149 and $199
- Only two figures are published per drug, so a three- or six-month plan cannot be priced without starting an intake
Navio MD
73/100Where the value is
- LegitScript certified with board-certified providers claimed
- Both compounded and brand-name options on one platform
- 48-state coverage with the two exclusions (AL, MS) explicitly disclosed rather than hidden
The tradeoffs
- No compounded semaglutide offered — only brand-name Ozempic for that molecule, at a much higher price than compounded competitors
- All prices are 'as low as' floors; the exact dose tied to each starting price is not published
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.